Brind.

ANI Pharmaceuticals achieved a Zacks Rank of #1 and a Momentum Style Score of A based on its stock performance compared to its industry benchmark.

5 reports, 1 independent Updated Aug 29
Gone quiet
Reports
5
Developments
2
Repetition
60%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

ANI Pharmaceuticals achieved a Zacks Rank of #1 and a Momentum Style Score of A based on its stock performance compared to its industry benchmark.

Who's involved

What this event is mainly about
ANI Pharmaceuticals (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. ANI Pharmaceuticals received a Zacks Rank of #1 and a Momentum Style Score of A.1 source
  2. ANI Pharmaceuticals achieved projected EPS growth of 39.5%, leading to top Zacks ratings.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksANI Pharmaceuticals (ANIP) is a Great Momentum Stock: Should You Buy? Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors
  • ZacksIs ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market'
  • ZacksIs Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amarin (AMRN) bee
  • ZacksANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run? Have you been paying attention to shares of ANI Pharmaceuticals (ANIP)? Shares have been on the move with the stock up 36
  • ZacksANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.38 per